Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background

Prescribing Fostair in Asthma

trimbow_subheader-mobile
Fostair gives you freedom to choose the appropriate device and strength for your patient.

Fostair pMDI and Fostair NEXThaler in 100/6 and 200/6 are indicated in the regular treatment of adult asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:1–4

  • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2-agonist or
  • patients already adequately controlled on both inhaled corticosteroids and long-acting β2-agonists
  • Fostair provides ICS continuity for adult patients already receiving maintenance treatment with beclometasone – a well-established molecule for the treatment of asthma5
  • Fostair contains formoterol, providing rapid bronchodilation within 1–3 minutes – as quick as reliever medication1–4,6

Fostair pMDI:
A familiar device with no need to shake before use2,4

  • Adult asthma
  • Maintenance and Reliever Therapy (MART) (only 100/6 licensed)
  • Can be used with the AeroChamber Plus® spacer device

AeroChamber Plus® is a registered trademark of Trudell Medical International

Fostair NEXThaler:
An easy-to-use device optimised for drug delivery and patient reassurance7–9
  • Adult asthma
  • Maintenance and Reliever Therapy (MART) (only 100/6 licensed)
The Fostair Range in adult asthma
Fostair® NEXThaler and pMDI devices 100/6

Fostair pMDI 100/6
Fostair NEXThaler 100/6

Both devices deliver 100 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate per inhalation.1,2

Fostair 100/6 is available for use as maintenance and reliever therapy (MART) in adult asthma.1,2

Fostair® NEXThaler and pMDI devices 200/6

Fostair pMDI 200/6
Fostair NEXThaler 200/6

Both devices deliver 200 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate per inhalation.3,4

How to prescribe Fostair

How to prescribe Fostair for maintenance therapy1–4

Low dose

Fostair 100/6:

One inhalation in the morning One inhalation in the evening

Medium dose

Fostair 100/6:

Two inhalations in the morning Two inhalations in the evening

High dose

Fostair 200/6:

Two inhalations in the morning Two inhalations in the evening

Fostair is indicated for the treatment of adult asthma (≥18 years).*1–4 Of the Fostair range, Fostair pMDI 100/6 and NEXThaler 100/6 are licensed for use as Maintenance and Reliever Therapy (MART).1,2

 

How to prescribe Fostair 100/6 for Maintenance and Reliever Therapy (MART):1,2

  • For maintenance:

One inhalation in the morning One inhalation in the evening

  • For relief:

    Patients should take one additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken (maximum daily dose is 8 inhalations).

Maintenance inhalations:2, Maximum reliever inhalations: 6, Maximum total inhalations: 8

*Full indication can be found within the prescribing information.

Fostair NEXThaler: optimised for drug delivery and patient reassurance[[7–9]]

An easy device to operate1,3,7

NEXThaler device opening - Open - NEXThaler device being used - Inhale - NEXThaler device being closed - Close

Full dose delivery8,10–14

Patients receive a full dose with consistent lung deposition, above a flow rate of 35 L/min8,10–14

Designed for patient reassurance1,3,7,8,11–14

Graphic - Ear - Click

Fostair NEXThaler’s audible ‘click’ reassures patients that the dose has been taken1,3,7

35 L/min

Fostair NEXThaler’s dose counter only counts successful individual inhalations, so each dose registered equals a dose taken1,3,7

With Fostair NEXThaler you know that no dose is wasted10

  • Fostair NEXThaler’s unique dose protector means the dose is only released on inhalation above a flow rate of 35 L/min, so you can be sure that all doses have been taken and none wasted10
  • Fostair NEXThaler’s dose counter only counts successful individual inhalations, so each dose registered equals a dose taken1,3

For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.

Click here for Fostair® (beclometasone/formoterol) Prescribing Information.

COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; MART: maintenance and reliever therapy; pMDI: pressurised metered dose inhaler.

References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
3. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
5. IQVIA BPI, MAT March 2020.
6. Ventolin Evohaler Summary of Product Characteristics. GlaxoSmithKline.
7. Voshaar T, et al. J Aerosol Med Pulm Drug Deliv. 2014; 27(5): 363–370.
8. De Backer W, et al. J Aerosol Med Pulm Drug Deliv. 2010; 23(3): 137–148.
9. Farkas A, et al. Int J Pharm. 2017; 533(1): 225–235.
10. Corradi M, et al. Expert Opin Drug Deliv. 2014; 11(9): 1497–1506.
11. Virchow JC, et al. J Aerosol Med Pulm Drug Deliv. 2018; 31(5): 269–280.
12. Buttini F, et al. J Aerosol Med Pulm Drug Deliv. 2016; 29(2): 167–178.
13. Pasquali I, et al. Resp Drug Deliv Eur. 2013;2:273-278.
14. Mariotti F, et al. Eur Resp J. 2011;38(Supp 55):830.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.